Buy Moderna (MRNA) stock [Updated daily] |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moderna stock

Own Moderna stock in just a few minutes.

Fact checked

Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. The vaccine has yet to be approved by the FDA, but the company has applied for emergency authorization and the first doses could be distributed this year, the Washington Post reported Nov. 30.
Here’s how to buy Moderna stock.

Latest updates

Tuesday, December 1: Advisors to the Center for Disease Control recommended that the first doses of any COVID-19 vaccine should be given to health-care workers and workers in nursing homes and other care facilities, according to news reports.

Monday, November 30: Moderna files for emergency authorization of its vaccine, and the Washington Post reports that 40 million dose of COVID-19 vaccines could be distributed by year’s end.

Monday, November 16: Moderna announces its vaccine is 94.5% effective based on late-stage trial data.

How to buy shares in Moderna

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Moderna. Find the stock by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Moderna. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Moderna’s COVID-19 vaccine

On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.

Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.

Moderna has now applied for emergency-use approval from the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.

In response to Moderna’s November announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.

Moderna vs. Pfizer

Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.

Type of vaccineMessenger RNA (mRNA)Messenger RNA (mRNA
Efficacy rate94.5%95%
Trial size30,000 people43,538 people
Number of doses2 shots, 28 days apart2 shots, 21 days apart
ProductionUp to 20 million doses by the end of 2020Up to 50 million doses by the end of 2020
Years in business10171
Number of manufactured drugs0300+

Moderna share price

Use our graph to track the performance of MRNA stocks over time.

Moderna shares at a glance

Information last updated 2021-03-06.
Previous closeUSD$N/A
Change USD$N/A
Change % N/A%
Volume 0
Information last updated 2021-03-03.
52-week rangeUSD$19.31 - USD$189.26
50-day moving average USD$156.5912
200-day moving average USD$106.9479
Wall St. target priceUSD$168.85
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.348

Buy Moderna shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moderna price performance over time

Historical closes compared with the close of $N/A from 2021-02-25

1 week (2021-02-23) N/A
1 month (2021-02-02) N/A
3 months (2020-12-02) N/A
6 months (2020-09-02) N/A
1 year (2020-03-02) N/A
2 years (2019-03-02) N/A
3 years (2018-03-02) N/A
5 years (2016-03-02) N/A

Moderna financials

Revenue TTM USD$803.4 million
Gross profit TTM USD$-574,877,000
Return on assets TTM -10.69%
Return on equity TTM -39.99%
Profit margin -92.99%
Book value $6.423
Market capitalisation USD$58.7 billion

TTM: trailing 12 months

Shorting Moderna shares

There are currently 14.7 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 26.5% down from 20.0 million last month.

There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 14.8 million). Moderna's SIR currently stands at 0.99. In other words for every 100,000 Moderna shares traded daily on the market, roughly 990 shares are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 40 shares are currently held short) or 0.0483% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna share price volatility

Over the last 12 months, Moderna's shares have ranged in value from as little as $19.31 up to $189.26. A popular way to gauge a stock's volatility is its "beta".

MRNA.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.5021. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moderna overview

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site